LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...
LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline...
Primary and secondary lung function endpoints met Results support twice-daily dosing LONDON and RALEIGH...
LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...
LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...
LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona...
Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private placement Commenced a pilot...
LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...
LONDON and RALEIGH, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...
LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...
LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...
LONDON and RALEIGH, N.C., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...
LONDON and RALEIGH, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...
Completed $200 million private placement post period Phase 3 COPD clinical trials planned to start later this...
LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads